Mircera Market Report 2026

Mircera Market Overview

• The Mircera market growth in the historic period has been driven by rising chronic kidney disease prevalence, limitations of short acting esas • Market expansion is supported by growth in aging population, increasing dialysis patient numbers • Growth Driver: Rising Prevalence Of Chronic Kidney Disease (CKD) Fuels Growth Of The Mircera Markt • Market Trend: Focus On Expanding Approved Solutions For CKD-Associated Anemia Treatment • North America was the largest region in 2025.

What Is Covered Under Mircera Market?

Mircera refers to a medication specifically formulated to treat anemia associated with chronic kidney disease (CKD). It is a long-acting erythropoiesis-stimulating agent (ESA) that promotes red blood cell production to maintain healthy hemoglobin levels. Mircera is typically administered through intravenous or subcutaneous injections and stands out for its extended dosing schedule, often requiring injections only once every two to four weeks. The main formulation types of mircera are injectable solutions and pre-filled syringes. Anemia due to chronic kidney disease refers to a condition where individuals with chronic kidney disease (CKD) experience a decrease in red blood cells, leading to anemia. The indications are anemia due to chronic kidney disease and anemia in cancer patients, and the distribution channels include hospitals, dialysis centers, specialty clinics, and retail pharmacies. It is used for various end-user patients, such as adult patients and geriatric patients.

What Is The Mircera Market Growth Forecast?

The mircera market size is expected to see strong growth in the next few years. It will grow to $3.69 million in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to growth in aging population, increasing dialysis patient numbers, demand for reduced injection frequency, expansion of specialty nephrology clinics, rising healthcare spending on ckd. Major trends in the forecast period include rising use of long acting esas, preference for extended dosing intervals, growing ckd patient population, increased treatment in dialysis centers, focus on stable hemoglobin management.

Global Mircera Market Segmentation

1) By Formulation: Injectable Solution, Pre-filled Syringes 2) By Indication: Anemia Due to Chronic Kidney Disease, Anemia in Cancer Patients 3) By Distribution Channel: Hospitals, Dialysis Centers, Specialty Clinics, Retail Pharmacies 4) By End User Patients: Adult Patients, Geriatric Patients

What Is The Driver Of The Mircera Market?

The rising prevalence of chronic kidney disease (CKD) is expected to propel the growth of mircera market going forward. Chronic kidney disease (CKD) is a health concern characterized by the gradual loss of kidney function, often associated with conditions such as diabetes and hypertension. The increasing incidence of chronic kidney disease (CKD) is driven by factors such as aging populations, lifestyle changes, and improved diagnostic practices. Anemia, a common complication of chronic kidney disease (CKD) caused by reduced erythropoietin production, necessitates the use of erythropoiesis-stimulating agents such as mircera to manage and stabilize hemoglobin levels effectively. For instance, in June 2023, according to the report published by Kidney Research UK, a UK-based non-profit organization, currently, approximately 7.2 million people in the UK are living with chronic kidney disease, representing over 10% of the population. Additionally, by 2033, the number of individuals affected by chronic kidney disease is projected to rise to 7.61 million. Therefore, the rising prevalence of chronic kidney disease (CKD) drives the mircera industry.

Key Players In The Global Mircera Market

Major companies operating in the mircera market are Roche

Global Mircera Market Trends and Insights

Major companies operating in the mircera market are focusing on developing approved solutions particulary for pediatric patients, for the treatment of anemia associated with chronic kidney disease. Pediatric patients with anemia due to chronic kidney disease (CKD) may benefit from Mircera (methoxy polyethylene glycol-epoetin beta), a long-acting erythropoiesis-stimulating agent (ESA) that helps stimulate red blood cell production, reducing the need for frequent injections, minimizing the risk of blood transfusions, and improving hemoglobin levels, thus enhancing overall growth, development, and quality of life. For instance, in April 2024, Vifor Pharma, a Switzerland-based pharmaceutical company, received expanded approval from the FDA for the use of Mircera (methoxy polyethylene glycol-epoetin beta) to include pediatric patients aged 3 months to 17 years who are experiencing anemia-associated with chronic kidney disease (CKD). This approval applies to both patients on dialysis and those not receiving dialysis, specifically for those transitioning from another erythropoiesis-stimulating agent (ESA) after their hemoglobin levels have been stabilized.

What Are Latest Mergers And Acquisitions In The Mircera Market?

In January 2023, AstraZeneca plc, a UK-based biopharmaceutical company, acquired CinCor Pharma, Inc., a US-based clinical-stage biopharmaceutical company, for a deal valued at up to $1.8 billion. With this acquisition, AstraZeneca aims to bolster its cardiorenal pipeline by gaining baxdrostat (CIN-107), a highly selective oral aldosterone synthase inhibitor targeting hypertension and chronic kidney disease. CinCor Pharma is a US-based company focused on developing novel small-molecule therapies for treatment-resistant hypertension, primary aldosteronism, and other cardio-renal disorders.

Regional Insights

North America was the largest region in the mircera market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Mircera Market?

The mircera market consists of sales of solutions and pre-filled syringes designed to treat anemia caused by chronic kidney disease (CKD). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Mircera Market Report 2026?

The mircera market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the mircera industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.